Abacus 3CP Hematology Analyzer Receives FDA Pre-Market Approval

Diatron Group (Diatron), global provider of hematology and clinical chemistry analyzers, has received US Food and Drug Administration (FDA) 510(k) pre-market approval for the Abacus 3CP, a fully automated, bench-top hematology analyzer. This follows the FDA approval in April of the Abacus 5, the most advanced model of Diatron’s range of hematology analyzers.

The Abacus 3CP analyzer is one of a range of three, 3-part differential analyzers from Diatron, which also includes the Abacus Junior 30 and Abacus 380. Together these offer between 12 and 20 parameters, with a throughput of 30 to 80 samples per hour. This provides flexible, cost-effective solutions for low to medium-sized customers. The Abacus 3CP processes up to 60 samples per hour, and has an internal memory capable of storing 10,000 records with full histograms and individual patient data.

Analyzers in the Abacus range possess easy-to-use, color touch screens with multilingual operating systems. Their compact size makes them ideal for physician’s offices or laboratories with minimal available desk-top space.

Commenting on the news, Jim Schepp, CEO at Diatron said: “We are delighted with this latest FDA approval of our Abacus 3CP hematology analyzer. It is a step forward for patient care in the US, as it allows hospital and physician office laboratories to access these instruments and benefit from this accurate and cost-effective technology”.

Diatron’s Abacus family of compact hematology analyzers provide high quality and fast complete blood count results making them suitable for laboratories, hospital clinics and physician offices.